Oncolytics Biotech (ONC) News Today C$0.77 -0.01 (-1.28%) As of 04/17/2025 03:59 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Buzz on the Bullboards: Energy, cannabis, and Biotech Shine on the TSXApril 17 at 10:49 AM | msn.comOncolytics Biotech (TSE:ONC) Sets New 1-Year Low - Here's What HappenedOncolytics Biotech (TSE:ONC) Reaches New 12-Month Low - Time to Sell?April 11, 2025 | marketbeat.comSmall-cap cancer therapy innovator raises $20M in flexible fundingApril 11, 2025 | msn.comOncolytics Biotech (TSE:ONC) Hits New 12-Month Low - Here's WhyOncolytics Biotech (TSE:ONC) Sets New 52-Week Low - Should You Sell?April 5, 2025 | marketbeat.comOncolytics Biotech (TSE:ONC) Hits New 1-Year Low - Time to Sell?Oncolytics Biotech (TSE:ONC) Hits New 52-Week Low - Here's WhyMarch 29, 2025 | marketbeat.comOncolytics Biotech Inc.March 24, 2025 | wsj.comOncolytics Biotech (TSE:ONC) Reaches New 12-Month Low - Here's WhyOncolytics Biotech (TSE:ONC) Reaches New 52-Week Low - Here's What HappenedMarch 19, 2025 | marketbeat.comHC Wainwright Has Optimistic View of TSE:ONC FY2026 EarningsOncolytics Biotech Inc. (TSE:ONC - Free Report) - Equities researchers at HC Wainwright boosted their FY2026 earnings per share (EPS) estimates for Oncolytics Biotech in a research report issued on Monday, March 10th. HC Wainwright analyst P. Trucchio now expects that the company will post earninMarch 14, 2025 | marketbeat.comLeede Financial Has Positive View of TSE:ONC FY2025 EarningsOncolytics Biotech Inc. (TSE:ONC - Free Report) - Leede Financial boosted their FY2025 earnings estimates for shares of Oncolytics Biotech in a research report issued to clients and investors on Monday, March 10th. Leede Financial analyst D. Loe now forecasts that the company will post earnings pMarch 14, 2025 | marketbeat.comFY2028 Earnings Forecast for TSE:ONC Issued By HC WainwrightOncolytics Biotech Inc. (TSE:ONC - Free Report) - Analysts at HC Wainwright dropped their FY2028 earnings estimates for shares of Oncolytics Biotech in a report issued on Monday, March 10th. HC Wainwright analyst P. Trucchio now expects that the company will post earnings per share of $0.57 for tMarch 13, 2025 | marketbeat.comOncolytics Biotech (TSE:ONC) Hits New 1-Year Low - Here's WhyOncolytics Biotech (TSE:ONC) Reaches New 1-Year Low - Here's WhyMarch 12, 2025 | marketbeat.comOncolytics Biotech: Continuing To Justify The NegativityMarch 11, 2025 | seekingalpha.comOncolytics price target lowered to C$5 from C$6 at RBC CapitalMarch 10, 2025 | markets.businessinsider.comOncolytics Biotech (TSE:ONC) Stock Price Down 9.3% - What's Next?Oncolytics Biotech (TSE:ONC) Shares Down 9.3% - What's Next?March 8, 2025 | marketbeat.comOncolytics Biotech Inc.: Oncolytics Biotech Reports Highlights and Financial Results for Q4 and Year-End 2024March 7, 2025 | finanznachrichten.deFrom Clinical Trials to the Market: Cancer Stocks With Big Potential in 2025March 7, 2025 | baystreet.caOncolytics reports Q4 EPS (10c) vs. (5c) last yearMarch 7, 2025 | markets.businessinsider.comOncolytics Biotech (TSE:ONC) Reaches New 12-Month Low - What's Next?Oncolytics Biotech (TSE:ONC) Hits New 52-Week Low - Here's What HappenedMarch 1, 2025 | marketbeat.comOncolytics Biotech And 2 Other Promising Penny Stocks On The TSXFebruary 7, 2025 | finance.yahoo.comOncolytics Biotech (TSE:ONC) Trading 2.9% Higher - Still a Buy?Oncolytics Biotech (TSE:ONC) Stock Price Up 2.9% - What's Next?February 6, 2025 | marketbeat.comFY2029 Earnings Estimate for TSE:ONC Issued By HC WainwrightOncolytics Biotech Inc. (TSE:ONC - Free Report) - Investment analysts at HC Wainwright issued their FY2029 earnings per share (EPS) estimates for shares of Oncolytics Biotech in a research report issued on Monday, February 3rd. HC Wainwright analyst P. Trucchio anticipates that the company will pFebruary 4, 2025 | marketbeat.comOncolytics Biotech (TSE:ONC) Sets New 52-Week Low - Here's WhyOncolytics Biotech (TSE:ONC) Sets New 12-Month Low - Should You Sell?February 3, 2025 | marketbeat.comH.C. Wainwright maintains $5 target on Oncolytics Biotech stockFebruary 3, 2025 | msn.comOncolytics Biotech (TSE:ONC) Shares Down 3.4% - Should You Sell?Oncolytics Biotech (TSE:ONC) Trading Down 3.4% - Should You Sell?January 17, 2025 | marketbeat.comOncolytics: PEI approves continuation of enrollment in Cohort 5 of GOBLET studyJanuary 16, 2025 | markets.businessinsider.comReplimune's SWOT analysis: biotech firm's stock poised for growth in oncologyJanuary 16, 2025 | msn.comGerman PEI approves enrolment in cohort 5 of Oncolytics’ pancreatic cancer trialJanuary 16, 2025 | finance.yahoo.comOncolytics Biotech (TSE:ONC) Stock Price Down 3.4% - Here's What HappenedOncolytics Biotech (TSE:ONC) Shares Down 3.4% - What's Next?January 15, 2025 | marketbeat.comUSA News Group: Cutting-Edge Cancer Therapies Lead the Way into a Transformative YearJanuary 15, 2025 | finanznachrichten.deInvestors Eye Biotech Stocks as Cancer Therapies Take Center Stage in 2025January 15, 2025 | baystreet.caOncolytics Biotech (TSE:ONC) Shares Pass Below 200-Day Moving Average - Here's WhyOncolytics Biotech (TSE:ONC) Stock Price Crosses Below 200 Day Moving Average - Here's What HappenedJanuary 14, 2025 | marketbeat.comOncolytics Biotech: Stocks Undervalued by Analyst Consensus on TSX (ONC)January 4, 2025 | theglobeandmail.comOncolytics Biotech (TSE:ONC) Shares Cross Above 200-Day Moving Average - Here's What HappenedOncolytics Biotech (TSE:ONC) Share Price Passes Above 200 Day Moving Average - What's Next?January 4, 2025 | marketbeat.comOncolytics Biotech (TSE:ONC) Stock Passes Above 200 Day Moving Average - Here's WhyOncolytics Biotech (TSE:ONC) Share Price Crosses Above 200-Day Moving Average - Here's WhyDecember 27, 2024 | marketbeat.comUSA News Group: Oncology in Focus: How Emerging Therapies Are Reshaping Cancer TreatmentDecember 26, 2024 | finanznachrichten.deOncology in Focus: How Emerging Therapies Are Reshaping Cancer TreatmentDecember 26, 2024 | tmcnet.comUSA News Group: Oncology Advancements Accelerate Amid Rising Early-Onset Cancer DiagnosesDecember 20, 2024 | finanznachrichten.deOncolytics Biotech Unveils Promising Cancer Therapy ResultsDecember 19, 2024 | markets.businessinsider.comOncolytics Biotech (TSE:ONC) Stock Price Up 14.5% - Here's What HappenedOncolytics Biotech (TSE:ONC) Trading Up 14.5% - Here's What HappenedDecember 19, 2024 | marketbeat.comOncolytics Biotech (TSE:ONC) Sets New 12-Month Low - What's Next?Oncolytics Biotech (TSE:ONC) Hits New 52-Week Low - Here's WhyDecember 16, 2024 | marketbeat.comOncolytics: DSMB recommended continued enrollment in Cohort 5 of GOBLET studyDecember 4, 2024 | markets.businessinsider.comOncolytics Biotech Progresses with GOBLET Cancer TrialDecember 4, 2024 | markets.businessinsider.comBiotech Advances Drive Cancer Research as Global Rates Continue Upward TrendDecember 2, 2024 | baystreet.caReplimune Stock Hits 1-Year High In After-hours As Small-Cap Biotech Files For FDA Approval Of Skin Cancer Combo Therapy: Retail UpbeatNovember 22, 2024 | msn.comFY2024 EPS Estimates for TSE:ONC Lowered by AnalystOncolytics Biotech Inc. (TSE:ONC - Free Report) - Analysts at Cantor Fitzgerald dropped their FY2024 earnings estimates for Oncolytics Biotech in a report issued on Wednesday, November 13th. Cantor Fitzgerald analyst L. Chen now expects that the company will post earnings of ($0.42) per share forNovember 18, 2024 | marketbeat.comFY2024 EPS Estimates for TSE:ONC Cut by HC WainwrightOncolytics Biotech Inc. (TSE:ONC - Free Report) - Equities research analysts at HC Wainwright reduced their FY2024 EPS estimates for shares of Oncolytics Biotech in a research note issued to investors on Wednesday, November 13th. HC Wainwright analyst P. Trucchio now expects that the company willNovember 18, 2024 | marketbeat.comLeede Financial Comments on TSE:ONC FY2024 EarningsOncolytics Biotech Inc. (TSE:ONC - Free Report) - Research analysts at Leede Financial issued their FY2024 earnings per share estimates for shares of Oncolytics Biotech in a report released on Wednesday, November 13th. Leede Financial analyst D. Loe anticipates that the company will post earningsNovember 18, 2024 | marketbeat.comRaymond James Upgrades Oncolytics Biotech (TSE:ONC) to "Moderate Buy"Raymond James raised Oncolytics Biotech to a "moderate buy" rating in a report on Thursday.November 16, 2024 | marketbeat.comHC Wainwright Brokers Raise Earnings Estimates for TSE:ONCOncolytics Biotech Inc. (TSE:ONC - Free Report) - Analysts at HC Wainwright upped their FY2028 earnings per share (EPS) estimates for Oncolytics Biotech in a research report issued on Wednesday, November 13th. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings pNovember 15, 2024 | marketbeat.comWhat is Raymond James' Forecast for TSE:ONC FY2024 Earnings?Oncolytics Biotech Inc. (TSE:ONC - Free Report) - Investment analysts at Raymond James lowered their FY2024 EPS estimates for shares of Oncolytics Biotech in a research note issued on Tuesday, November 12th. Raymond James analyst R. Sarugaser now anticipates that the company will post earnings peNovember 15, 2024 | marketbeat.com Get Oncolytics Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for ONC and its competitors with MarketBeat's FREE daily newsletter. Email Address ONC Media Mentions By Week ONC Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ONC News Sentiment▼-0.620.49▲Average Medical News Sentiment ONC News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ONC Articles This Week▼31▲ONC Articles Average Week Get Oncolytics Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for ONC and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Aptose Biosciences News Fennec Pharmaceuticals News Theratechnologies News Medicenna Therapeutics News Covalon Technologies News Sernova News Microbix Biosystems News Devonian Health Group News Sirona Biochem News Hemostemix News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (TSE:ONC) was last updated on 4/18/2025 by MarketBeat.com Staff From Our PartnersElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | SponsoredClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | SponsoredThe first casualty of the 2025 trade warThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncolytics Biotech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oncolytics Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ONC Stock Free ONC Stock Alerts